StreetInsider.com News Articles

H.C. Wainwright Reiterates Buy Rating on Aligos Therapeutics Inc. (ALGS)

Tue, 14 Jul 2026 07:04:47 -0400

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $50.00 price target on Aligos Therapeutics Inc. (NASDAQ: ALGS).

The analyst commented: "On July 13, Aligos announced completion of enrollment in the Phase 2 trial (B-SUPREME) evaluating pevifoscorvir sodium (pevy; formerly ALG-000184) vs tenofovir disoproxil fumarate (TDF) in chronic hepatitis B virus (HBV) infection. In our follow-up call with Aligos, management confirmed that all 245 participants—131 hepatitis B e antigen (HBeAg)-positive and 114 HBeAg-negative—are included in the primary efficacy cohorts, while the paired-biopsy cohorts are separate. The HBeAg-negative cohort exceeded its 100-patient target because a surge of already-in-screening patients qualified after

Aligos completes enrollment in phase 2 HBV drug study

Mon, 13 Jul 2026 08:00:17 -0400

Aligos Therapeutics, Inc. (Nasdaq: ALGS) announced the completion of enrollment in its Phase 2 B-SUPREME study evaluating pevifoscorvir sodium for the treatment of chronic hepatitis B virus (HBV) infection, according to a press release from the South San Francisco-based company.

The study enrolled 131 HBeAg+ participants in Part 1a and 114 HBeAg- participants in Part 2a. Because Part 1a exceeded its planned enrollment target, a second interim analysis for sample size re-estimation will not be conducted. Topline safety and efficacy data are expected in late third quarter of 2027.

The B-SUPREME study (NCT06963710) is a randomized, double-blind, active-controlled multicenter trial comparing pevifoscorvir

Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection

Mon, 13 Jul 2026 08:00:00 -0400

Topline data expected to be available late 3Q2027

SOUTH SAN FRANCISCO, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it has completed enrollment of both the HBeAg+ (Part 1a) and HBeAg- (Part 2a) participants in the Phase 2 B-SUPREME study of pevifoscorvir sodium, under development for the treatment of chronic hepatitis B virus (HBV) infection. Topline safety and efficacy data are expected to be available in late third quarter of 2027.

Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection

Mon, 13 Jul 2026 08:00:00 -0400

Topline data expected to be available late 3Q2027

H.C. Wainwright Reiterates Buy Rating on Aligos Therapeutics Inc. (ALGS)

Wed, 08 Jul 2026 06:44:29 -0400

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $50.00 price target on Aligos Therapeutics Inc. (NASDAQ: ALGS).

The analyst commented: "Pevy’s dual role as a chronic-suppression therapy and future functional-cure backbone differentiates it across the hepatitis drug development landscape. On June 24, we hosted an H.C. Wainwright At Home fireside chat with Aligos Therapeutics Chairman, President, and CEO Lawrence Blatt, Ph.D., M.B.A., focused on pevifoscorvir sodium (pevy; formerly ALG-000184) which is being evaluated in the Phase 2 B-SUPREME trial in hepatitis B virus (HBV), and Aligos’ broader pipeline in hepatitis delta virus (HDV), and metabolic dysfunction-associated steatohepatitis (MASH). The

Aligos receives $25M upfront from China license deal for HBV drug

Mon, 06 Jul 2026 16:05:26 -0400

Aligos Therapeutics (NASDAQ: ALGS) announced it has received a $25 million upfront payment from Xiamen Amoytop Biotech Co., Ltd. under an exclusive license agreement covering pevifoscorvir sodium in Greater China for the treatment of chronic hepatitis B virus (HBV) infection.

Under the terms of the deal, Aligos is eligible to receive up to $420 million in clinical, regulatory, and sales milestone payments, along with tiered, high single-digit royalties on net sales within Amoytop's licensed territories. Aligos retains all development and commercialization rights for pevifoscorvir sodium in the United States, Europe, South Korea, Japan, and all other markets.

China's National Medical Products Administration

Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection

Mon, 06 Jul 2026 16:05:00 -0400

Breakthrough Therapy Designation granted for pevifoscorvir sodium in China

SOUTH SAN FRANCISCO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it has received the upfront payment of $25M USD from the exclusive license deal of pevifoscorvir sodium in Greater China with Xiamen Amoytop Biotech Co., Ltd. (Amoytop). In addition, pevifoscorvir sodium was granted Breakthrough Therapy Designation from the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA).

Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection

Mon, 06 Jul 2026 16:05:00 -0400

Breakthrough Therapy Designation granted for pevifoscorvir sodium in China

Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection

Mon, 06 Jul 2026 16:05:00 -0400

Breakthrough Therapy Designation granted for pevifoscorvir sodium in China

Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection

Mon, 06 Jul 2026 16:05:00 -0400

Breakthrough Therapy Designation granted for pevifoscorvir sodium in China

Form 4 Aligos Therapeutics, For: Jun 25 Filed by: Chavez Margarita

Mon, 29 Jun 2026 16:38:00 -0400

si-local-file:///var/storage/secattach/20260629/26707044.html

Form 4 Aligos Therapeutics, For: Jun 25 Filed by: Chavez Margarita

Mon, 29 Jun 2026 16:38:00 -0400

si-local-file:///var/storage/secattach/20260629/26707044.html

Form 4 Aligos Therapeutics, For: Jun 25 Filed by: Preston Heather

Mon, 29 Jun 2026 16:38:00 -0400

si-local-file:///var/storage/secattach/20260629/26707055.html

Form 4 Aligos Therapeutics, For: Jun 25 Filed by: Preston Heather

Mon, 29 Jun 2026 16:38:00 -0400

si-local-file:///var/storage/secattach/20260629/26707055.html

Form 4 Aligos Therapeutics, For: Jun 25 Filed by: Scopa James Paul

Mon, 29 Jun 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260629/26707019.html

Form 4 Aligos Therapeutics, For: Jun 25 Filed by: Scopa James Paul

Mon, 29 Jun 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260629/26707019.html

Form 4 Aligos Therapeutics, For: Jun 25 Filed by: Martell Bridget A

Mon, 29 Jun 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260629/26707030.html

Form 4 Aligos Therapeutics, For: Jun 25 Filed by: Martell Bridget A

Mon, 29 Jun 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260629/26707030.html

Form 4 Aligos Therapeutics, For: Jun 25 Filed by: Hirth Peter

Mon, 29 Jun 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260629/26707004.html

Form 4 Aligos Therapeutics, For: Jun 25 Filed by: Hirth Peter

Mon, 29 Jun 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260629/26707004.html

Form 4 Aligos Therapeutics, For: Jun 25 Filed by: Nuechterlein Carole

Mon, 29 Jun 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260629/26707014.html

Form 4 Aligos Therapeutics, For: Jun 25 Filed by: Nuechterlein Carole

Mon, 29 Jun 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260629/26707014.html

Form 8-K Aligos Therapeutics, For: Jun 25

Fri, 26 Jun 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260626/26698623.html

Form 8-K Aligos Therapeutics, For: Jun 25

Fri, 26 Jun 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260626/26698623.html

Form SCHEDULE 13D Aligos Therapeutics, Filed by: BLATT LAWRENCE

Wed, 24 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260624/26685964.html